MLP's Q3 results reveal strong core business performance despite a reduced FY'25 EBIT guidance. We recommend BUY due to solid underlying profitability and favorable long-term outlook.
14 Nov 2025
Q3 review: PW, but healthy and de-risked core business
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Q3 review: PW, but healthy and de-risked core business
MLP's Q3 results reveal strong core business performance despite a reduced FY'25 EBIT guidance. We recommend BUY due to solid underlying profitability and favorable long-term outlook.